[1] Westerterp M, van Westreenen HL, Reitsma JB, et al. Esophageal cancer:CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy systematic review. Radiology, 2005, 236(3):841-851.
[2] 章斌, 吴翼伟, 王振欣, 等. 18F-FLT PET/CT显像在鼻咽癌诊断及分期中的应用.中华核医学杂志, 2011, 31(5):306-309.
[3] Debucquoy A, Devos E, Vermaelen P, et al. 18F-FLT and 18F-FDG PET to measure response to radiotherapy combined with celecoxib in two colorectal xenograft models. Int J Radiat Biol, 2009, 85(9):763-771.
[4] Wei LH, Su H, Hildebrandt IJ, et al. Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma. Clin Cancer Res, 2008, 14(11):3416-3426.
[5] Aide N, Kinross K, Cullinane C, et al. 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model. J Nucl Med, 2010, 51(10):1559-1564.
[6] Ullrich RT, Zander T, Neumaier B, et al. Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine([F]FLT)positron emission tomography(PET). PLoS One, 2008, 3(12):e3908.
[7] Uddin MK, Reignier SG, Coulter T, et al. Syntheses and antiproliferative evaluation of oxyphenisatin derivatives. Bioorg Med Chem Lett, 2007, 17(10):2854-2857.
[8] Jensen MM, Erichsen KD, Björkling F, et al. Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice. PLoS One, 2010, 5(9):e12965.
[9] Rosenberg B, Vancamp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature, 1965, 205(4972):698-699.
[10] Leyton J, Latigo JR, Perumal M, et al.Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res, 2005, 65(10):4202-4210.
[11] Guchelaar HJ, Hoekstra HJ, de Vries EG, et al. Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumours of the extremities. Br J Cancer, 1992, 65(6):898-902.
[12] Been LB, Suurmeijer AJ, Elsinga PH, et al. 18F-fluorodeoxythymidine PET for evaluating the response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcomas. J Nucl Med, 2007, 48(3):367-372.
[13] van Westreenen HL, Heeren PA, Jager PL, et al. Pitfalls of positive findings in staging esophageal cancer with F-18-fluorodeoxyglucose positron emission tomography. Ann Surg Oncol, 2003, 10(9):1100-1105.
[14] Yue J, Chen L, Cabrera AR, et al. Measuring tumor cell proliferation with 18F-FLT PET during radiotherapy of esophageal squamous cell carcinoma: a pilot clinical study. J Nucl Med, 2010, 51(4):528-534.
[15] Han D, Yu J, Yu Y, et al. Comparison of 18F-fluorothymidine and 18F-fluorodeoxyglucose PET/CT in delineating gross tumor volume by optimal threshold in patients with squamous cell carcinoma of thoracic esophagus. Int J Radiat Oncol Biol Phys, 2010, 76(4):1235-1241.
[16] Giammarile F, Billotey C, Lombard-Bohas C, et al. 18F-FLT and 18F-FDG positron emission tomography for the imaging of advanced well-differentiated gastro-entero-pancreatic endocrine tumors. Nucl Med Commun, 2011, 32(2):91-97.
[17] Been LB, Hoekstra HJ, Suurmeijer AJ, et al.[18F]FLT-PET and [18F]FDG-PET in the evaluation of radiotherapy for laryngeal cancer. Oral Oncol, 2009, 45(12):e211-215.
[18] Apisarnthanarax S, Alauddin MM, Mourtada F, et al. Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models. Clin Cancer Res, 2006, 12(15):4590-4597.
[19] Goldberg N, Kundel Y, Purim O, et al. Early prediction of histopathological response of rectal tumors after one week of preoperative radiochemotherapy using 18F-FDG PET-CT imaging. A prospective clinical study. Radiat Oncol, 2012, 7: 124.
[20] Oyama N, Ponde DE, Dence C, et al. Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. J Nucl Med, 2004, 45(3):519-525.
[21] Sugiyama M, Sakahara H, Sato K, et al. Evaluation of 3'-deoxy-3'-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. J Nucl Med, 2004, 45(10):1754-1758.